ALK and lung adenocarcinoma: Of this total, approximately 50% of lung adenocarcinomas are molecularly subdivided, and their treatment depends on the presence of different molecular alterations, including EGFR mutations and ALK or ROS1 fusions, that confer sensitivity to selective kinase inhibitors107.